FindTrial
Sign In

Chemoradiotherapy Vs chemoradiotherapy with intraluminal brachytherapy is compared for treatment of ca esophagus

TO COMPARE THE OUTCOME AND TOXICITY OF CONCOMITANT CHEMORADIOTHERAPY Vs CONCOMITANT CHEMORADIOTHERAPY FOLLOWED BY INTRALUMINAL BRACHYTHERAPY IN MIDDLE ONE-THIRD OF CARCINOMA ESOPHAGUS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/01/016826
Enrollment
50
Registered
2019-01-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C154- Malignant neoplasm of middle thirdof esophagus

Interventions

Intervention1: â??TO COMPARE THE OUTCOME AND TOXICITY OF CONCOMITANT CHEMORADIOTHERAPY Vs CONCOMITANT CHEMORADIOTHERAPY FOLLOWED BY INTRALUMINAL BRACHYTHERAPY IN MIDDLE ONE-THIRD OF CARCINOMA ESOPHAGU

Sponsors

IGMC Shimla
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All histologically proven cases of middle one â?? third of esophageal carcinoma 2. Previously untreated. 3. Lesions not more than 10 cm on barium swallow and endoscopy. 4. Karnofsky Performance status (KPS) of more than 60%. 5. Age of the patients should be 30-70yrs.

Exclusion criteria

Exclusion criteria: 1. Patient not willing to give consent 2. Patient who has already received radiotherapy 3. Patients with distant metastasis. 4. Age >70 years & 5. Deranged KFT (BUN or serum creatinine 2 times above the normal) 6. Deranged LFT (Bilirubin 2 times above the normal limit)

Design outcomes

Primary

MeasureTime frame
Â¥ To compare the disease response in concomitant chemoradiation vs chemoradiation followed by intraluminal brachytherapy in middle one third of carcinoma esophagus. Â¥ To compare quality of life and to find out the tolerability and toxicity profile in concomitant chemoradiation vs concomitant chemoradiation followed by intraluminal brachytherapy in middle one third of carcinoma esophagus. Timepoint: 1st follw up : 2months after completion of treatment—

Secondary

MeasureTime frame
To compare quality of life and to find out the tolerability and toxicity profile in concomitant chemoradiation vs concomitant chemoradiation followed by intraluminal brachytherapy in middle one third of carcinoma esophagus.Timepoint: At the end of treatment at first FU—

Countries

India

Contacts

Public ContactDR Shabnum thakur

IGMC SHIMLA H.P

mg9122@rediffmail.com9418455673

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026